Table 2.
Analysis of FANCC variants (p.R158X and p.R548X combined) by tumour subtype.
| Stratum | Cases | Odds Ratio (95% CI) | p |
|---|---|---|---|
| ER-negative | 5/10,124 | 0.91 (0.35; 2.37) | 0.845 |
| ER-positive | 14/40,855 | 0.67 (0.37; 1.28) | 0.223 |
| TNBC | 2/4,126 | 0.89 (0.21; 3.77) | 0.877 |
| Ductal | 6/36,695 | 0.33 (0.13; 0.80) | 0.014 |
| Lobular | 4/6,842 | 1.27 (0.43; 3.69) | 0.665 |
| High grade | 3/14,582 | 0.39 (0.12; 1.31) | 0.129 |
| Node-positive | 1/15,937 | 0.14 (0.02; 1.00) | 0.050 |
| Familial | 7/9,720 | 1.01 (0.43; 2.35) | 0.988 |
| Premenopausal | 12/22,232 | 1.09 (0.55; 2.16) | 0.814 |
| Bilateral | 0/2,741 | — | 0.645 |
Association analyses of FANCC variants p.R158X and p.R548X with breast cancer risk for subgroups. Results are given as odds ratios (OR) with 95% confidence interval (CI) and p-value (p). Cases in subgroups were compared to the frequency 26/ 49,793 for all controls (derived from Table 1). Familial cases were defined as those with a first-degree family history of breast cancer; premenopausal cases were those with age at diagnosis <50 years. ER, estrogen-receptor; TNBC, triple-negative breast cancer.